Live Feeds
● LIVE Updated 2d ago · 14 sources tracked

This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.

Definium Therapeutics reported strong results from its Phase 3 Emerge study for DT120 ODT, an LSD-based depression pill. A single dose significantly reduced major depressive disorder symptoms in a 149-patient trial. The company's stock rose sharply following the announcement on June 22, 2026.

RSS Source map (14)

What changed

The company released topline Phase 3 data for its DT120 depression treatment.

Live updates

  1. Definium Therapeutics Shares Surge After Phase 3 Depression Trial Success

    Definium Therapeutics reported strong results from its Phase 3 Emerge study for DT120 ODT, an LSD-based depression pill. A single dose significantly reduced major depressive disorder symptoms in a 149-patient trial. The company's stock rose sharply following the announcement on June 22, 2026.

    What's confirmed:

    • Definium Therapeutics' LSD-based drug DT120 ODT met its primary and key secondary endpoints in the Phase 3 Emerge trial.
    • The Emerge trial included 149 patients with major depressive disorder.
    • The primary endpoint was met with a statistical significance of p
    • Definium Therapeutics shares surged on Monday, June 22, 2026, following the clinical results.
    • The CEO described the trial results as the "best data ever seen."
    • Definium is currently awaiting data from a second pivotal trial.

    Still unconfirmed:

    • Definium Therapeutics shares jumped 64% premarket.
    • The company announced a large capital raise.
    • Definium shares surged 50% to a more than four-year high.
    • Shares of Definium Therapeutics surged approximately 55% in premarket trading.
    confidence 95%